- Trial phase
- Phase 2 (pivotal/registrational)
- Time to market
- If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
- Why 4/10
- No hard, dated binary catalyst (PDUFA or pivotal topline readout) is scheduled within the next ~12 months. The pivotal Phase 2 trial is enrolling, with the remaining 9 patients expected to be dosed by mid-2027 and 12-month co-primary endpoints, pushing topline data to 2028. The drug is a major value driver for RCKT but the company also has the approved KRESLADI product, reducing single-asset concentration.
Watch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.
Price Chart
Executive Summary
RP-A501 is an AAV9 gene therapy from Rocket Pharmaceuticals (RCKT) being developed as a one-time treatment for Danon disease, a fatal X-linked genetic cardiomyopathy with no approved therapies. The program has had a turbulent history: Phase 1 data published in NEJM showed promising long-term efficacy, but a patient death in May 2025 triggered an FDA clinical hold. After a protocol amendment with recalibrated dosing, the hold was lifted and the first 3 patients under the modified protocol showed positive safety. In September 2026, the FDA aligned on a pivotal pathway accepting a 12-patient efficacy cohort with 12-month co-primary endpoints intended to support potential accelerated approval. The remaining 9 patients are expected to be dosed by mid-2027, pushing topline data to 2028. The stock trades near its 52-week low (~$2.36) with a mean analyst target of $8.58, reflecting both the program's potential and the long, risky road ahead.
How It Works
RP-A501 is a one-time gene therapy that uses a harmless adeno-associated virus (AAV9) to deliver a working copy of the LAMP2 gene directly into heart muscle cells. Danon disease is caused by mutations in the LAMP2 gene, which leads to progressive, fatal heart muscle weakening (cardiomyopathy). By restoring the missing protein, the therapy aims to stop or reverse the heart damage.
Trial Status
The global pivotal Phase 2 trial is actively enrolling. Three patients have been treated under a modified (lower-dose) protocol with positive safety data reported in August 2026. The FDA confirmed these 3 patients count toward the 12-patient pivotal efficacy population. Rocket expects to dose the remaining 9 patients by mid-2027. The co-primary endpoints are measured at 12 months post-treatment. Updated clinical findings were presented at an investor webinar on October 6, 2026.
The Two-Sided Case
Upcoming Catalysts
- Enrollment updates for the remaining 9 patients in the pivotal Phase 2 trial
- Potential interim data presentations at medical conferences in 2027
- KRESLADI commercial revenue updates (already FDA-approved) that could provide non-dilutive funding
- Any regulatory updates or FDA interactions regarding the accelerated approval pathway
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ROCKET PHARMACEUTICALS, INC. CLUSTER RCKT ·Originating report